Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00778609 |
The aim of the present study is to investigate whether women taking a new combined oral contraceptive pill (SH T00658ID, estradiol valerate/dienogest) experience fewer hormone withdrawal-associated symptoms such as pelvic pain or headache during their monthly cycle compared to a commonly used contraceptive pill (Microgynon®).
Condition | Intervention | Phase |
---|---|---|
Oral Contraceptive Headache Pelvic Pain |
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID) Drug: Encapsulated Microgynon + Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Efficacy Study |
Official Title: | A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, 2-Arm Study to Investigate the Effect of Estradiol Valerate/Dienogest Compared to Microgynon on Hormone Withdrawal Associated Symptoms in Healthy Women After 6 Cycles |
Estimated Enrollment: | 880 |
Study Start Date: | December 2008 |
Estimated Study Completion Date: | April 2010 |
Estimated Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm 1: Experimental |
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval
|
Arm 2: Active Comparator |
Drug: Encapsulated Microgynon + Placebo
Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
|
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
- Women with any contraindication for oral contraceptive use
Contact: Bayer Clinical Trials Contact | clinical-trials-contact@bayerhealthcare.com |
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Bayer Schering Pharma AG ( Therapeutic Area Head ) |
Study ID Numbers: | 91550, EudraCT: 2008-003226-42, 310787 |
Study First Received: | October 22, 2008 |
Last Updated: | December 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00778609 |
Health Authority: | Australia: Department of Health and Ageing Therapeutic Goods Administration; Finland: National Agency for Medicines; France: Afssaps - French Health Products Safety Agency; Germany: Federal Institute for Drugs and Medical Devices; Mexico: Federal Commission for Protection Against Health Risks; Spain: Spanish Agency of Medicines; Switzerland: Swissmedic; Thailand: Food and Drug Administration; United Kingdom: Medicines and Healthcare Products Regulatory Agency; United States: Food and Drug Administration |
Combined Oral Contraceptives Pelvic Pain Headache |
Estradiol valerate Ethinyl Estradiol Pain Healthy Estradiol 17 beta-cypionate Estradiol Norgestrel Signs and Symptoms |
Pelvic Pain Estradiol 3-benzoate Levonorgestrel Headache Neurologic Manifestations Ethinyl Estradiol-Norgestrel Combination Polyestradiol phosphate Dienogest |
Contraceptives, Oral, Combined Contraceptives, Postcoital, Synthetic Contraceptive Agents Therapeutic Uses Contraceptives, Oral Physiological Effects of Drugs |
Nervous System Diseases Contraceptive Agents, Female Contraceptives, Oral, Synthetic Reproductive Control Agents Contraceptives, Postcoital Pharmacologic Actions |